Surgery Partners Balances Growth Ambitions With Rising Headwinds

Surgery Partners Inc. ((SGRY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Surgery Partners walked a tightrope of cautious optimism on its latest earnings call. Management highlighted in‑line revenue and EBITDA, strong momentum in higher‑acuity procedures, and solid physician recruitment, but also acknowledged softer case growth, payer and tax headwinds, rising interest costs, and leverage that limit near‑term upside.

Quarterly Results Delivered, But Not Spectacular

Net revenue reached about $811 million in the quarter, with adjusted EBITDA around $102 million and a 12.6% margin, essentially matching expectations. Same‑facility net revenue rose 4.4% and operating cash flow roughly doubled year over year to $12 million, signaling steady but unspectacular progress.

Musculoskeletal and Robotics Drive Higher Acuity

Musculoskeletal procedures remained a standout, with total joint surgeries in ASCs growing 14.6% from a year earlier. The company now operates 73 surgical robots, which management said are supporting a richer acuity mix and helping shift more complex cases into outpatient settings.

Physician Recruitment and De Novo Pipeline Support Growth

Surgery Partners recruited roughly 140 physicians in the quarter, focused on orthopedics, ophthalmology, and GI, reinforcing key service lines. The company opened one new facility and has added nine de novos over the past year, with more openings expected later this year and several in the pipeline to fuel returns on invested capital.

Cost Controls Deliver Sequential Margin Tailwinds

Cost management showed tangible progress, with supply expense improving to about 27.2% of net revenue and salaries, wages, and benefits dropping to roughly 30.5%. Management pointed to sequential gains in labor and supply metrics and ongoing initiatives aimed at expanding margins despite external pressures.

Same‑Facility Case Growth Falls Below the Algorithm

Same‑facility case growth was just 0.6% in the quarter, well below the company’s long‑term targets and the prior year’s pace. Executives attributed roughly 40 basis points of the shortfall to weather‑related deferrals in higher‑volume, lower‑acuity specialties such as GI and ophthalmology, suggesting some volume may shift into later periods.

Payer Mix and Provider Taxes Weigh on Earnings

Payer mix remained a modest drag, with commercial payors holding around 50% of volume and lingering pressure from recent trends. New provider taxes and a Medicaid rate cut, combined with higher other operating costs now at about 7.3% of revenue, are expected to reduce full‑year adjusted earnings by roughly $8 million.

Incentive Compensation to Lift Costs Back Toward Normal

Management reset incentive compensation programs, which will increase SWB expense starting in the second quarter and more notably in the third. While framed as a return to normal after prior restraint, the change will create a headwind to margins even as the company pushes further cost containment.

Higher Interest Expense Highlights Leverage Risk

Interest expense rose by about $7 million year over year after the expiration of an interest rate swap, underscoring the cost of the capital structure. GAAP net debt to adjusted EBITDA sits near 5.1x, with net leverage under the credit agreement at roughly 4.3x, leaving investors attuned to cash interest and deleveraging progress.

M&A Activity Lags Ambitions Amid Timing Uncertainty

Despite targeting around $200 million of annual M&A deployment, only about $4 million was deployed on acquisitions in the quarter. Management emphasized that deal timing remains unpredictable and noted that current full‑year guidance does not bake in any upside from potential transactions.

Working Capital and Collections Offer Cash‑Flow Upside

Days sales outstanding held steady at roughly 66 days, indicating room to tighten collections and unlock cash. Leadership called out working capital discipline at the facility level and improved DSO as key levers to convert more of the company’s EBITDA into sustainable free cash flow.

Surgical Hospital Portfolio Faces Pockets of Complexity

A small group of surgical hospitals continues to face operational headwinds, complicating the broader portfolio story. Remediation and optimization efforts are underway, including advanced discussions in one large market targeted for mid‑2026, but management acknowledged the timing and ultimate outcomes remain uncertain.

Guidance Reaffirmed With Emphasis on Discipline

The company reaffirmed 2026 guidance for revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, assuming no M&A contribution. Management expects the second quarter to represent about 24%–24.5% of annual revenue and 23%–23.5% of EBITDA, while maintaining a focus on disciplined capital deployment and gradual deleveraging.

Surgery Partners’ call painted a picture of a business with solid fundamentals and promising growth engines, but also meaningful financial and operational constraints. Investors will be watching whether robust MSK and robotics growth, new physician additions, and ongoing cost controls can offset payer and tax headwinds, rising interest expense, and softer case growth over the coming quarters.